Gilead Sciences Inc
(LTS:0QYQ)
$
89.755
0.23 (0.26%)
Market Cap: 112.32 Bil
Enterprise Value: 132.90 Bil
PE Ratio: 109.56
PB Ratio: 6.12
GF Score: 75/100 Gilead Sciences Inc at Wells Fargo Healthcare Conference Transcript
Sep 08, 2022 / 02:25PM GMT
Release Date Price:
$65.28
(+1.91%)
Mohit Bansal
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Great. Thank you very much for this session. My name is Mohit Bansal. I'm 1 of the biopharma analysts here at Wells Fargo. And with us, we have Andy, the CFO of Gilead. Thank you very much, Andy, for joining us.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Thank you for having us. Happy to be here.
Questions & Answers
Mohit Bansal
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst
Thank you very much. And then maybe we can begin this session today. I mean you just dropped some interesting data this morning for Trodelvy. So can you talk a little bit about that? And how do you think about the data at this point?
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Sure. Yes. No, it's exciting data. So just to be clear on what Mohit's referring to. This is the Late-breaking abstract at ESMO on the Trodelvy TROPiCS-02 data
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot